Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANTENGENE-B

4.890
+0.0400.82%
Volume:234.50K
Turnover:1.12M
Market Cap:3.32B
PE:-8.68
High:4.890
Open:4.730
Low:4.700
Close:4.850
52wk High:8.160
52wk Low:0.600
Shares:679.00M
HK Float Shares:679.00M
Volume Ratio:1.54
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.564
ROE:-25.98%
ROA:-13.05%
PB:3.96
PE(LYR):-8.68
PS:35.93

Loading ...

Antengene Corporation H1 Revenue RMB 53.2 Million

THOMSON REUTERS
·
Aug 22

Antengene's Cancer Therapy ATG-022 Granted Breakthrough Therapy Designation in China

MT Newswires Live
·
Aug 19

Antengene's Atg-022 (Cldn18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

THOMSON REUTERS
·
Aug 19

Antengene - Atg-022 Granted Breakthrough Therapy Designation for Gastric Cancer by Center for Drug Evaluation (Cde) of China Nmpa

THOMSON REUTERS
·
Aug 19

ANTENGENE-B (06996) Shareholders Deposit Shares into Standard Chartered Bank (Hong Kong) with Market Value of HK$416 Million

Stock News
·
Aug 19

BUZZ-HK-listed Antengene at 2-1/2-year peak on Xpovio approval in China

Reuters
·
Jul 29

Antengene Gets China Nod for New Indication of Multiple Myeloma Drug

MT Newswires Live
·
Jul 28

Antengene Corporation Ltd. Secures Regulatory Approval for XPOVIO® in China for Second-Line Treatment of Multiple Myeloma

Reuters
·
Jul 28

Antengene Corp - Xpovio Approved in China for Second-Line Multiple Myeloma Treatment

THOMSON REUTERS
·
Jul 28

Antengene Corporation Ltd. Unveils Promising Phase I/II Study Results for ATG-022 at ESMO 2025

Reuters
·
Jul 28

BOCOM International: Innovative Drug Sector's Recovery Prospects Remain Attractive; Focus on Commercial Insurance Drug Catalog Launch

Stock News
·
Jul 16

Antengene Corporation Ltd. Conducted Annual General Meeting

Reuters
·
Jun 13

Antengene Corporation Ltd. Announces Global Clinical Collaboration with MSD to Evaluate ATG-022 in Combination with KEYTRUDA® for Advanced Solid Tumors

Reuters
·
May 20